CAS 2305154-31-6

N-(3-Bromo-2-fluorophenyl)-7,8-dihydro-[1,4]dioxino[2,3-g]quinazolin-4-amine

CAS : 2305154-31-6

Formule : C₁₆H₁₁BrFN₃O₂

Degré de pureté : 98%

Masse moléculaire : 376.1798

Ref: IN-DA01KK6J

N-(3-Bromo-2-Fluorophenyl)-7,8-Dihydro-[1,4]Dioxino[2,3-G]Quinazolin-4-Amine

CAS : 2305154-31-6

N-(3-Bromo-2-Fluorophenyl)-7,8-Dihydro-[1,4]Dioxino[2,3-G]Quinazolin-4-Amine

Degré de pureté : 99%

Masse moléculaire : 376.18g/mol

Ref: 54-PC108670

JCN037

CAS : 2305154-31-6

JCN037

Degré de pureté : ≥98%

Masse moléculaire : 376.18g/mol

Ref: 54-BUP09867

JCN037

CAS : 2305154-31-6

JCN037 is potent, non-covalent and brain-penetrant inhibitor of EGFR(EGFR, p-wtEGFR and pEGFRvⅢ with IC50 of 2.49 nM, 3.95 nM, 4.48 nM , respectively).

Formule : C₁₆H₁₁BrFN₃O₂

Degré de pureté : 99.5%

Couleur et forme : Solid

Masse moléculaire : 376.18

Ref: TM-T8431

JCN037

CAS : 2305154-31-6

JCN037 is a potent, selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor in clinical development for the treatment of malignant brain tumors. JCN037 has been shown to potently inhibit EGFR tyrosine kinase activity in vitro and in vivo, with an IC50 of 0.2 nM and 1 nM respectively. JCN037 has a high affinity for the EGFR, with a Kd of 2.5 nM and it inhibits EGFR-mediated signaling by binding to the ATP site on the EGFR protein. The selectivity profile of JCN037 was characterized by its ability to inhibit tyrosine kinases other than EGFR with an IC50 > 100 μM. This molecule also blocks tumor cell proliferation by inhibiting downstream signaling pathways such as epidermal growth factor (EGF) receptor activation and phosphorylation of ERKs and Akt, which are important molecules involved in cell

Formule : C₁₆H₁₁BrFN₃O₂

Degré de pureté : Min. 95%

Masse moléculaire : 376.18 g/mol

Ref: 3D-FSD15431